CDK8 and neoplasm: In contrast, inhibition of ERK and CDK8/19 delayed the acquisition of resistance (Fig. 5f), resulting in a 34% reduction in tumor weight at study endpoint (Fig. 5g) without additional toxicity (Fig. 5h).